Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Context: Lipodystrophy syndromes are a heterogeneous group of rare genetic or acquired disorders characterized by generalized or partial loss of adipose tissue. LMNA-related lipodystrophy syndromes are classified based on the severity and distribution of adipose tissue loss.

Objective: We aimed to annotate all clinical and metabolic features of patients with lipodystrophy syndromes carrying pathogenic LMNA variants and assess potential genotype-phenotype relationships.

Methods: We retrospectively reviewed and analyzed all our cases (n = 115) and all published cases (n = 379) curated from 94 studies in the literature.

Results: The study included 494 patients. The most common variants in our study, R482Q and R482W, were associated with similar metabolic characteristics and complications though those with the R482W variant were younger (aged 33 [24] years vs 44 [25] years; P < .001), had an earlier diabetes diagnosis (aged 27 [18] vs 40 [17] years; P < .001) and had lower body mass index levels (24 [5] vs 25 [4]; P = .037). Dyslipidemia was the earliest biochemical evidence described in 83% of all patients at a median age of 26 (10) years, while diabetes was reported in 61% of cases. Among 39 patients with an episode of acute pancreatitis, the median age at acute pancreatitis diagnosis was 20 (17) years. Patients who were reported to have diabetes had 3.2 times, while those with hypertriglyceridemia had 12.0 times, the odds of having pancreatitis compared to those who did not.

Conclusion: This study reports the largest number of patients with LMNA-related lipodystrophy syndromes to date. Our report helps to quantify the prevalence of the known and rare complications associated with different phenotypes and serves as a comprehensive catalog of all known cases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10876415PMC
http://dx.doi.org/10.1210/clinem/dgad606DOI Listing

Publication Analysis

Top Keywords

lipodystrophy syndromes
16
lmna-related lipodystrophy
12
adipose tissue
8
years 001
8
median age
8
acute pancreatitis
8
patients
6
lipodystrophy
5
cases
5
years
5

Similar Publications

Human immunodeficiency virus (HIV)-associated lipodystrophy is a well-recognized complication of long-term antiretroviral therapy (ART), characterized by abnormal fat distribution. In the head and neck, it typically present as an obtuse heavy neck combined with accelerated midfacial atrophy, causing significant aesthetic concerns and psychosocial distress. Conventional treatments, including ART modifications, have limited effectiveness, and changes are often irreversible.

View Article and Find Full Text PDF

Genetic mutations affecting proteasome function can result in multi-organ diseases, such as Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. Neurological symptoms associated with CANDLE suggest that proteasomal mutations may impact neuronal development and/or function. We generated cerebral organoids (COs) from CANDLE patient induced pluripotent stem cells (iPSCs), which exhibited impaired neuronal development when compared to COs from healthy control iPSCs.

View Article and Find Full Text PDF

Clinical Guidance for Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment.

Curr Diab Rep

September 2025

Metabolism, Endocrinology and Diabetes (MEND) Division, Internal Medicine Department, University of Michigan, 2800 Plymouth Road Building 25, Room 3696, Ann Arbor, MI, 48105, USA.

Purpose Of Review: The goal of this review is to address the challenges in diagnosing and managing lipodystrophy syndromes.

Recent Findings: Clinical and metabolic assessments, along with genetic analyses, are essential for tailoring medical care and providing appropriate genetic counseling. Efforts are underway to develop more objective diagnostic tools using imaging techniques or novel biomarkers.

View Article and Find Full Text PDF

The clinical approach to child and adolescent patients with lipodystrophy: a series of international case discussions.

Front Endocrinol (Lausanne)

August 2025

German Center for Child and Adolescent Health (DZKJ), Ulm Site, Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany.

Introduction: Lipodystrophy syndromes comprise a group of rare endocrine disorders characterized by the generalized or partial loss of adipose tissue. Affected individuals frequently display absolute or relative reductions in leptin, a key adipokine regulator of hunger-satiety signaling, and are predisposed to a range of metabolic and end-organ complications, often from a young age. The presentation and severity of lipodystrophy syndromes is largely dependent on the extent of adipose tissue loss while comorbidities often deteriorate with age.

View Article and Find Full Text PDF

Lipodystrophy Syndromes: One Name but Many Diseases Highlighting the Importance of Adipose Tissue in Metabolism.

Curr Diab Rep

August 2025

Metabolism, Endocrinology and Diabetes (MEND) Division, Internal Medicine Department, University of Michigan, 2800 Plymouth Road Building 25, Room 3696, Ann Arbor, MI, 48105, USA.

Purpose Of Review: This review aims to introduce the latest developments in etiology and classification of lipodystrophy syndromes.

Recent Findings: Recent developments in genetic assessment with deeper sequencing have increased the number of specific etiologies of lipodystrophy with known single-gene associations. Despite this, more than 50% of patients diagnosed with partial and most of acquired lipodystrophy do not have a precise disease mechanism.

View Article and Find Full Text PDF